Acumen Pharmaceuticals is focused on developing targeted therapies for Alzheimer’s disease, with a particular emphasis on addressing the role of toxic amyloid-beta oligomers (AβOs) in the progression of the disease. Their lead candidate, sabirnetug (ACU193), is a monoclonal antibody specifically designed to selectively target and inhibit these toxic soluble AβOs. By preventing AβOs from binding to synapses, sabirnetug aims to preserve neuronal function and potentially provide both symptomatic relief and disease-modifying benefits for patients with early Alzheimer’s disease. This innovative approach is based on extensive research indicating that AβOs are a primary driver of neurodegeneration and associated cognitive decline.

The company’s pipeline includes ongoing clinical trials, such as the Phase 2 ALTITUDE-AD study, which evaluates the efficacy and safety of intravenous sabirnetug in early Alzheimer’s patients. Acumen's strategy is to leverage a deep understanding of the various forms of amyloid beta species, particularly the toxic oligomers, to develop a treatment that not only targets the underlying causes of Alzheimer’s but also offers improved safety and efficacy compared to existing therapies. The focus on AβOs represents a shift from traditional approaches that have primarily targeted amyloid plaques, positioning Acumen at the forefront of Alzheimer’s disease research and treatment innovation.

United States

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers.

Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

Central Nervous System (CNS)

Nervous System Diseases

Acumen Pharmaceuticals

Alzheimer's disease

<p class="font_7">ACU193 is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration.</p>

Acumen Pharmaceuticals

Company Details